Santhera Pharmaceuticals Holding AG (0QN1) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon ladies and gentlemen and welcome to the Sancero Pharmaceuticals half year results investor presentation. Throughout this meeting attendees online will be in listen only mode. Questions are encouraged, they can be submitted at any time via the Q&A tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself, however the company can review all questions submitted today and will post your responses where it's appropriate to do so. Before we begin, we would just like to submit the following poll, and if you could give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the team from Santerra Pharmaceuticals. Catherine Shabir, good afternoon. Good afternoon, everyone, and welcome again to the interim results for the six months ending the 30th of June, 2025. Giving the presentation today is myself, Catherine Isted, the CFO, as well as our Chief Medical Officer, Dr. Shabir Hassan. Unfortunately, our CEO, Dario Eklund, cannot be with us today as he's actually had a recent operation on his shoulder, but he will be back with us shortly. As was said in the introduction, there will be an opportunity to ask questions at the end of the presentation, so please add these into the box as we go along. To start with, as always, we have a disclaimer. Please feel free to read this at your leisure. While I appreciate this is a results call, we thought it's worthwhile spending a bit of time going through who Sanfera is and what we do, and also a reminder about the D&D market. So I will start off with this small snapshot of the company. So we are a Swiss-li...